Filing Summary
Company: Unicycive Therapeutics, Inc. Filing: Form 8-K, Item 8.01, reporting an event dated September 3, 2026. The report was signed September 28, 2026.
Business Context and Event
On September 3, 2026, a securities class action was filed against the company and certain officers in the U.S. District Court for the Northern District of California. The suit concerns public statements relating to the company’s new drug application for oxylanthanum carbonate, a phosphate binder for hyperphosphatemia in chronic kidney disease patients on dialysis.
Financial Information
This 8-K does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial results, and does not quantify the potential financial impact of the lawsuit.
Management Position, Risks, and Outlook
The company says it believes the claims are meritless and intends to vigorously defend the lawsuit. The filing provides no guidance, litigation timeline, details of the alleged statements, or estimate of potential costs or exposure. The litigation is a contingent risk; its outcome and impact are not established in this filing.
Important Facts to Verify
- The complaint, allegations, requested relief, and any subsequent court filings.
- The specific company statements at issue and the company’s responses.
- Any later disclosure of litigation costs, potential exposure, or effects on the oxylanthanum carbonate application.